Decoy Therapeutics
DCOY
3 hedge funds and large institutions have $62.1K invested in Decoy Therapeutics in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 5 closing their positions.
0.12% less ownership
Funds ownership: 4.47% → 4.35% (-0.12%)
39% less capital invested
Capital invested by funds: $102K → $62.1K (-$39.8K)
57% less funds holding
Funds holding: 7 → 3 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$44.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.93K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$661 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HKAM
Horizon Kinetics Asset Management
New York
|
-$16.4K |
| 2 |
Renaissance Technologies
New York
|
-$15K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$13.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.7K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$661 |
DCOY Hedge Fund Activity: Q2 2024 in Review
3 of the 6,939 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2024, worth a combined $62.1K — down 39% from $102K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of DCOY and 1 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Armistice Capital, adding an estimated $44.9K. The largest seller was Horizon Kinetics Asset Management, exiting entirely with an estimated $16.4K sold.
- 3 institutional investors held Decoy Therapeutics (DCOY) as of Q2 2024, down from 7 in Q1 2024.
- Funds reported $62.1K of Decoy Therapeutics stock for Q2 2024, down 39% quarter-over-quarter.
- 1 fund opened new Decoy Therapeutics positions in Q2 2024 and 5 closed out, a net change of -4 holders.
- The largest Decoy Therapeutics buyer in Q2 2024 was Armistice Capital, an estimated $44.9K added.
- The largest Decoy Therapeutics seller in Q2 2024 was Horizon Kinetics Asset Management, an estimated $16.4K sold.
Based on aggregated 13F filings for Q2 2024.